Change in Management at Accovion GmbH

ESCHBORN, Germany--Accovion GmbH today announced that Dr. Andree Beckerling has been named the new Chief Executive Officer of Accovion GmbH effective January 1, 2014. He succeeds Martin Schröder, who has ended his active duty at Accovion and will remain available to the company as a shareholder. Mr. Schröder worked for Accovion for eight years and has successfully positioned the company, after the spin-off from Aventis, as an independent full-service provider.

Dr. Clemens Doppler, Chairman of the Board of Accovion GmbH: "We cordially thank Mr. Schröder for his valuable contribution to Accovion over many successful years and wish him all the best. Under his leadership Accovion has been successfully positioned as a full-service provider in the highly competitive CRO market. With Dr. Beckerling we have gained an outstanding experienced personality under who's leadership Accovion's continous development as a leading independent European full-service provider will be consequently driven forward."

Dr. Beckerling, who has served as a member of Accovion's management team since 2011 and was responsible for the medical business unit of the company, brings in 15 years of experience in clinical development in the international CRO industry.

"I look forward to our upcoming tasks and challenges. Together with the strong management team and qualified staff, we will continue the successful development of Accovion and broaden our clinical expertise as well as our international presence, especially throughout Europe," emphasizes Dr. Beckerling. "Our clients' satisfaction with our services is my personal goal. Therefore, quality, reliability and flexibility will remain the values that our clients can expect from Accovion as their trusted partner. Together with our business partners, we look to the future with confidence," adds Dr. Beckerling.

Accovion, headquartered in Eschborn/Frankfurt, is a leading independent European provider of comprehensive services in the sphere of clinical development of drugs and medical devices, and is currently active in more than 20 countries.